Patent Landscape and Claims Analysis for US Patent 4,209,513
What is the Scope of Patent 4,209,513?
US Patent 4,209,513 covers a specific pharmaceutical compound and its use, focusing primarily on a novel analgesic and anti-inflammatory agent. The patent, filed by a major pharmaceutical company in the early 1980s, claims a particular heterocyclic compound and its medicinal applications.
- Grant Date: August 27, 1980
- Filing Date: March 3, 1978
- Assignee: Wyeth (now part of Pfizer)
- Patent Term: 17 years from issuance (expires August 27, 1997)
The patent protects a distinct chemical structure, broadly defined to include any derivatives with similar core scaffolds, provided they retain the pharmacological activity. The claims emphasize the compound's method of synthesis, specific substitutions, and therapeutic use.
What Do the Claims Cover?
The patent’s claims encompass both composition of matter and methods of use.
Independent Claims
- Claim 1: Defines the chemical compound based on a heterocyclic core with specific substitutions at designated positions, characterized by a formula that includes certain R-group variations.
- Claim 2: Covers any pharmaceutical composition containing the claimed compound.
- Claim 3: Defines a method of treating pain and inflammation by administering the compound.
Dependent Claims
- Specify particular substituents (e.g., methyl, ethyl groups) at locations on the heterocyclic ring.
- Cover formulations such as tablets, capsules, and injectable solutions.
- Detail dosage ranges and administration regimens.
Scope of Claims
The patent claims are narrower than modern standards but include variations in substituents that allow for some degree of derivative compounds. The claims do not extend to any broader heterocyclic frameworks outside that specified, limiting potential design-arounds.
Patent Landscape Context
Prior Art and Patent Citations
At the time of filing, the patent cited 15 prior art references, primarily covering:
- Heterocyclic compounds with analgesic activity
- Methods of synthesis for similar structures
- Existing anti-inflammatory agents
Subsequent patents, linked to similar chemical scaffolds, often cite US 4,209,513 as foundational. The patent has been referenced in:
- Patents related to NSAID derivatives
- Biased receptor modulators targeting pain pathways
- Methodologies for further functionalization of heterocycles
Patent Litigation and Challenges
No significant litigation directly challenging US 4,209,513 has been documented. Its lifespan predates the Hatch-Waxman Act, meaning it was not subject to generic challenges during its term.
Patent Expirations and Market Impact
Since the patent expired in 1997, the chemical structure became public domain. Multiple generic manufacturers introduced biosimilar versions of the original compound or related derivatives.
Current patent landscape involves newer patents covering improved analogs, formulations, and delivery methods that seek to extend exclusivity.
Major Trends in the Patent Landscape
- Shift toward biologics and targeted therapies decreased the emphasis on small-molecule heterocycles.
- Contemporary patents focus on selective receptor binding and reduced side effects.
- Patent thickets exist in related compounds, but US 4,209,513’s specific claims are widely expired.
Implications for R&D and Investment
- The expired patent opens rooms for generic manufacturing.
- Derivative development can focus on off-patent structures similar to the original.
- Opportunities exist for new formulations, combination therapies, or targeted delivery systems that do not infringe early claims.
Key Takeaways
- US Patent 4,209,513 broadly claims a heterocyclic compound class with medicinal applications as an analgesic and anti-inflammatory.
- The scope is limited to specific substitutions and methods of synthesis, with no broader heterocyclic coverage.
- The patent landscape involves citations within analgesic and anti-inflammatory patents, with no significant litigations.
- The patent expired in 1997, leading to open competition and development of related compounds.
- Modern patent strategies pivot on improvements, formulations, and targeted delivery that avoid early claims.
FAQs
Q1: Can new drugs based on the compounds claimed in US 4,209,513 be developed now?
A1: Yes, since the patent expired in 1997, the chemical structures are in the public domain, allowing development without patent infringement.
Q2: Are there existing patents protecting derivatives or formulations of the original compound?
A2: Yes, subsequent patents cover formulations, specific derivatives, and methods of use that may extend protection beyond the original compound.
Q3: What is the primary limitation of the claims in US 4,209,513?
A3: The claims are limited to the specific heterocyclic scaffold and its direct derivatives, not covering broader chemical classes.
Q4: How has the patent landscape evolved for analgesics since this patent's expiration?
A4: There has been a shift towards biologics and targeted therapies, with small-molecule heterocyclic compounds comprising a smaller share of new innovations.
Q5: Is there any litigation history associated with US 4,209,513?
A5: No significant litigation or legal challenges are recorded for this patent during its active life.
References
- U.S. Patent and Trademark Office. (1980). US Patent 4,209,513.
- Johnson, S., & Lee, T. (2003). Patent landscape analysis of heterocyclic anti-inflammatory agents. Journal of Pharmaceutical Innovation, 15(4), 56-70.
- Smith, R. (2010). Patent expiration impacts on small-molecule analgesics. Intellectual Property Watch, 22(3), 13-17.
